All Content Outsourced Pharma

1. Quantifying Single-Use Waste Produced During mAb Manufacture 4/2/2026

   Discover the current scale of plastic single-use technology waste and its projected growth, specifically for the biomanufacturing domain. There is an increasing need for sustainable solutions.

2. Symbiosis Expands Commercial Capabilities With Addition Of New Stability Chamber 4/1/2026

   Symbiosis Pharmaceutical Services (Symbiosis), a Contract Development and Manufacturing Organisation (CDMO) specialising in the sterile GMP manufacturer of injectable drug products, has expanded its Quality Control (QC) laboratory with the installation of a new 30°C stability chamber.

3. Digital Standardization: Accelerating Gene Therapy Tech Transfer With Confidence And Compliance 4/1/2026

   Fragmented, manual data practices slow tech transfer and increase risk; centralized digital CMC systems standardize workflows, improve transparency, and accelerate onboarding while maintaining compliance.

4. NuTekBio Facilities Tour 4/1/2026

   An animal‑free raw material partner delivering precision manufacturing, audit‑ready compliance, and tailored variability control—helping biopharma scale faster with lower risk and confidence.

5. The Effect Of Conventional Cooling Versus Controlled Ice Nucleation On Primary Drying Time 4/1/2026

   See how controlled ice nucleation shortens lyophilization cycles, supports higher drying temperatures, and reduces complexity for amorphous and mixed formulations without sacrificing quality.

6. ROIS CDMO Closes On The Acquisition Of US Injectable Manufacturing Facility 4/1/2026

   ROIS, the CDMO arm of ROVI and a leader in injectable manufacturing, today announces closing the acquisition of a state-of-the-art injectable drug product manufacturing and packaging site in Phoenix, Arizona (USA) from Bristol Myers Squibb.

7. Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected For cGMP Manufacturing 4/1/2026

   Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has entered into a development and manufacturing agreement with Cytovance Biologics (www.cytovance.com), a leading full-service contract development and manufacturing organization ("CDMO") specializing in mammalian and microbially expressed biologics, to produce cGMP clinical materials for its planned Phase 2 clinical trial of its breast cancer vaccine.

8. Merck Completes Acquisition Of JSR Life Sciences' Chromatography Business, Expanding Protein A Capabilities And Downstream Portfolio 4/1/2026

   Merck, a leading science and technology company, today announced that it has successfully closed the acquisition of the chromatography business of JSR Life Sciences.

9. From QM To QMM For AI-Assisted Pharmaceutical Manufacturing Operations 4/1/2026

   The FDA’s focus has shifted from tracking quality metrics to promoting quality management maturity. AI/ML is poised to help with efforts, though it introduces additional complexity around data integrity.

10. Swiss Rockets Collaborates With Lonza To Advance Torqur's Oncology Drug Candidate Bimiralisib Into Late-Stage Clinical Development 3/31/2026

    Torqur AG, an innovative clinical-stage biotechnology company dedicated to advancing treatments for oncology and dermatology, and Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), announced a manufacturing agreement for the clinical supply of bimiralisib, an investigational therapy being explored across multiple indications, with its most advanced program in development for the treatment of actinic keratosis (AK).